Clinical Trials · NCT02501161
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,012
- Start date
- Jan 2016
- Locations
- 143 sites, 16 countries
- Primary endpoint
- Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification